Synexus Enrolls Patients For Hypertension Study
Synexus has recruited the highest number of patients for a major global study. The company has recruited 1,221 patients at seven UK sites, averaging 174 patients per site,
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.
Elan and Transition Therapeutics has presented phase 1 data, which demonstrated that treatment with ELND005 (scyllo-inositol) has achieved desired concentrations in human brain tissue and cerebrospinal fluid. ELND005